TY  - EJOU
AU  - Sașco, S. Daniela
AU  - Dumitrel, D. Ștefania-Irina
AU  - Smultea, S. Ioan
AU  - Smeu, S. Andreea
TI  - Hesperidin as a Potential Candidate for Improving the Response of Detroit 562 cells to Cisplatin—An In Vitro Study
T2  - Journal of Experimental Pharmacology and Toxicology

PY  - 2026
VL  - 4
IS  - 1
SN  - 3091-0595

AB  - Background: Oropharyngeal squamous cell carcinoma (OPSCC) is one of the most common cancers globally, occurring in all types of populations, but current therapy faces multiple barriers, urgently requiring new alternatives for improvement. Hesperidin (HSP) is a bioflavonoid with pleiotropic properties that has been mentioned in studies for enhancing response to chemotherapy, including in the case of cisplatin (CIS). Methods: Using Detroit 562 cells, HSP, CIS, and the combinatorial treatment of the two were examined by MTT assay, morphological analysis, and mitochondrial and nuclear assessment for 24 h. Results: The results showed that the combination of HSP+CIS produces superior effects, reducing cell viability by up to 16%and producing cell rounding and shrinkage and significant alterations in nuclei and mitochondria compared to individual treatments. Conclusions: HSP may be an important candidate in improving CIS cytotoxicity in Detroit 562 cells and could be considered a promising natural adjuvant. The combined treatment of the phytocompound and CIS led to superior outcomes, enhancing the effects of CIS.
KW  - hesperidin
KW  - cisplatin
KW  - combinatorial treatment
KW  - oropharyngeal squamous cell carcinoma
DO  - 10.6425/042026jept003